Effects of NSAIDs on beagle crevicular cyclooxygenase metabolites and periodontal bone loss

This investigation focuses on the changes in the concentrations of cyclooxygenase (CO) products present within the crevicular fluid in naturally‐progressing periodontitis in the beagle and the effects of various non‐steroidal anti‐inflammatory drugs (NSAIDs) on these metabolite levels and disease pr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of periodontal research 1992-05, Vol.27 (3), p.207-213
Hauptverfasser: Offenbacher, S., Williams, R. C., Jeffcoat, M. K., Howell, T. H., Odle, B. M., Smith, M. A., Hall, C. M., Johnson, H. G., Goldhaber, P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 213
container_issue 3
container_start_page 207
container_title Journal of periodontal research
container_volume 27
creator Offenbacher, S.
Williams, R. C.
Jeffcoat, M. K.
Howell, T. H.
Odle, B. M.
Smith, M. A.
Hall, C. M.
Johnson, H. G.
Goldhaber, P.
description This investigation focuses on the changes in the concentrations of cyclooxygenase (CO) products present within the crevicular fluid in naturally‐progressing periodontitis in the beagle and the effects of various non‐steroidal anti‐inflammatory drugs (NSAIDs) on these metabolite levels and disease progression. Six groups of 5–6 beagles with periodontitis were followed for 6 months to determine the pretreatment rate of radiographic bone loss. At baseline, groups of animals were placed on soft chow to promote disease progression. Groups were treated with either placebo, three different formulations of systemic ibuprofen, systemic naproxen or topical flurbiprofen. During the 6‐month treatment phase, crevicular fluid (CF) samples and radiographs were taken at regular intervals. Radioimmunoassay of CF samples from untreated animals demonstrated a steady increase in prostaglandin E2 (PGE 2) over baseline values. At 1 month, CF‐PGE2 levels increased 2‐fold over baseline and, by 6 months, had reached a 5‐ to 6‐fold elevation. Crevicular fluid thromboxane B2 (CF‐TxB2) levels rapidly reached a 4‐ to 5‐fold peak over baseline at 1 month and subsequently dropped to a 2‐fold elevation for the remainder of the study. The rate of bone loss (BLOSS) in untreated animals increased 38% during the 6‐month period, as compared to baseline pretreatment BLOSS rates. Overall, there was a significant depression in the CF levels of both PGE2 and TxB2 in all NSAID‐treated groups. All NSAID treatments significantly retarded BLOSS, ranging from 21.0–36.9% of the control BLOSS rate. The topical application of flurbiprofen was as effective in depressing CF levels of PGE2 and TxB2 as systemic or sustained release formulations of other NSAIDs. The data further substantiate the concept that much of the BLOSS that occurs in periodontal disease is mediated by products of the cyclooxygenase pathway. Furthermore, CO activation represents a major regulatory step in bone destruction and may thereby serve as an important site for pharmacological modulation.
doi_str_mv 10.1111/j.1600-0765.1992.tb01670.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72996984</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72996984</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5027-70cb0daaec2dd48de79c5865a843a115c3eeced9d4cba0105895f4b8be604f563</originalsourceid><addsrcrecordid>eNqVkF1v0zAUhi0EGqXwE5AshLhLcOLYjrlAGlsZm6bxrSFxYfnjZErnxsVOof33uEpVrvGNbZ33POfoQehFRcoqn9fLsuKEFERwVlZS1uVoSMUFKbcP0OxYeohmhNR1QZu2eYyepLQk-c-FPEEnOdQS2szQz0XXgR0TDh2--Xp6eZ5fAzag7zxgG-F3bzdeR2x31oew3d3BoBPgFYzaBN-PkLAeHF5D7IMLw6g9NmEA7ENKT9GjTvsEzw73HH1_v_h29qG4_nhxeXZ6XVhGalEIYg1xWoOtnWtaB0Ja1nKm24bqqmKWAlhw0jXWaFIR1krWNaY1wEnTMU7n6NXEXcfwawNpVKs-WfBeDxA2SYlaSi4zbY7eTEEb83oROrWO_UrHnaqI2ptVS7XXp_b61N6sOphV29z8_DBlY1bg_rVOKnP95aGuk9W-i3qwfTrGGOVNRuXY2yn2p_ew-48F1NWXRU1EBhQToE8jbI8AHe8VF1QwdXtzoT5_uqI_3tFzdUv_AlGmpcc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72996984</pqid></control><display><type>article</type><title>Effects of NSAIDs on beagle crevicular cyclooxygenase metabolites and periodontal bone loss</title><source>Wiley-Blackwell Journals</source><source>MEDLINE</source><creator>Offenbacher, S. ; Williams, R. C. ; Jeffcoat, M. K. ; Howell, T. H. ; Odle, B. M. ; Smith, M. A. ; Hall, C. M. ; Johnson, H. G. ; Goldhaber, P.</creator><creatorcontrib>Offenbacher, S. ; Williams, R. C. ; Jeffcoat, M. K. ; Howell, T. H. ; Odle, B. M. ; Smith, M. A. ; Hall, C. M. ; Johnson, H. G. ; Goldhaber, P.</creatorcontrib><description>This investigation focuses on the changes in the concentrations of cyclooxygenase (CO) products present within the crevicular fluid in naturally‐progressing periodontitis in the beagle and the effects of various non‐steroidal anti‐inflammatory drugs (NSAIDs) on these metabolite levels and disease progression. Six groups of 5–6 beagles with periodontitis were followed for 6 months to determine the pretreatment rate of radiographic bone loss. At baseline, groups of animals were placed on soft chow to promote disease progression. Groups were treated with either placebo, three different formulations of systemic ibuprofen, systemic naproxen or topical flurbiprofen. During the 6‐month treatment phase, crevicular fluid (CF) samples and radiographs were taken at regular intervals. Radioimmunoassay of CF samples from untreated animals demonstrated a steady increase in prostaglandin E2 (PGE 2) over baseline values. At 1 month, CF‐PGE2 levels increased 2‐fold over baseline and, by 6 months, had reached a 5‐ to 6‐fold elevation. Crevicular fluid thromboxane B2 (CF‐TxB2) levels rapidly reached a 4‐ to 5‐fold peak over baseline at 1 month and subsequently dropped to a 2‐fold elevation for the remainder of the study. The rate of bone loss (BLOSS) in untreated animals increased 38% during the 6‐month period, as compared to baseline pretreatment BLOSS rates. Overall, there was a significant depression in the CF levels of both PGE2 and TxB2 in all NSAID‐treated groups. All NSAID treatments significantly retarded BLOSS, ranging from 21.0–36.9% of the control BLOSS rate. The topical application of flurbiprofen was as effective in depressing CF levels of PGE2 and TxB2 as systemic or sustained release formulations of other NSAIDs. The data further substantiate the concept that much of the BLOSS that occurs in periodontal disease is mediated by products of the cyclooxygenase pathway. Furthermore, CO activation represents a major regulatory step in bone destruction and may thereby serve as an important site for pharmacological modulation.</description><identifier>ISSN: 0022-3484</identifier><identifier>EISSN: 1600-0765</identifier><identifier>DOI: 10.1111/j.1600-0765.1992.tb01670.x</identifier><identifier>PMID: 1608034</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Administration, Oral ; Administration, Topical ; Alveolar Bone Loss - drug therapy ; Alveolar Bone Loss - metabolism ; Analysis of Variance ; Animals ; Anti-Inflammatory Agents, Non-Steroidal - administration &amp; dosage ; Anti-Inflammatory Agents, Non-Steroidal - pharmacology ; Biological and medical sciences ; bone loss ; Bones, joints and connective tissue. Antiinflammatory agents ; Cyclooxygenase Inhibitors - pharmacology ; cyclooxygenase metabolites ; Dentistry ; Dinoprostone - metabolism ; Dogs ; Flurbiprofen - administration &amp; dosage ; Flurbiprofen - pharmacology ; Gingival Crevicular Fluid - chemistry ; Ibuprofen - administration &amp; dosage ; Ibuprofen - pharmacology ; Medical sciences ; Naproxen - administration &amp; dosage ; Naproxen - pharmacology ; NSAIDs ; Pharmacology. Drug treatments ; Prostaglandins F - metabolism ; Thromboxane B2 - metabolism</subject><ispartof>Journal of periodontal research, 1992-05, Vol.27 (3), p.207-213</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5027-70cb0daaec2dd48de79c5865a843a115c3eeced9d4cba0105895f4b8be604f563</citedby><cites>FETCH-LOGICAL-c5027-70cb0daaec2dd48de79c5865a843a115c3eeced9d4cba0105895f4b8be604f563</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1600-0765.1992.tb01670.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1600-0765.1992.tb01670.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27915,27916,45565,45566</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=5364016$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1608034$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Offenbacher, S.</creatorcontrib><creatorcontrib>Williams, R. C.</creatorcontrib><creatorcontrib>Jeffcoat, M. K.</creatorcontrib><creatorcontrib>Howell, T. H.</creatorcontrib><creatorcontrib>Odle, B. M.</creatorcontrib><creatorcontrib>Smith, M. A.</creatorcontrib><creatorcontrib>Hall, C. M.</creatorcontrib><creatorcontrib>Johnson, H. G.</creatorcontrib><creatorcontrib>Goldhaber, P.</creatorcontrib><title>Effects of NSAIDs on beagle crevicular cyclooxygenase metabolites and periodontal bone loss</title><title>Journal of periodontal research</title><addtitle>J Periodontal Res</addtitle><description>This investigation focuses on the changes in the concentrations of cyclooxygenase (CO) products present within the crevicular fluid in naturally‐progressing periodontitis in the beagle and the effects of various non‐steroidal anti‐inflammatory drugs (NSAIDs) on these metabolite levels and disease progression. Six groups of 5–6 beagles with periodontitis were followed for 6 months to determine the pretreatment rate of radiographic bone loss. At baseline, groups of animals were placed on soft chow to promote disease progression. Groups were treated with either placebo, three different formulations of systemic ibuprofen, systemic naproxen or topical flurbiprofen. During the 6‐month treatment phase, crevicular fluid (CF) samples and radiographs were taken at regular intervals. Radioimmunoassay of CF samples from untreated animals demonstrated a steady increase in prostaglandin E2 (PGE 2) over baseline values. At 1 month, CF‐PGE2 levels increased 2‐fold over baseline and, by 6 months, had reached a 5‐ to 6‐fold elevation. Crevicular fluid thromboxane B2 (CF‐TxB2) levels rapidly reached a 4‐ to 5‐fold peak over baseline at 1 month and subsequently dropped to a 2‐fold elevation for the remainder of the study. The rate of bone loss (BLOSS) in untreated animals increased 38% during the 6‐month period, as compared to baseline pretreatment BLOSS rates. Overall, there was a significant depression in the CF levels of both PGE2 and TxB2 in all NSAID‐treated groups. All NSAID treatments significantly retarded BLOSS, ranging from 21.0–36.9% of the control BLOSS rate. The topical application of flurbiprofen was as effective in depressing CF levels of PGE2 and TxB2 as systemic or sustained release formulations of other NSAIDs. The data further substantiate the concept that much of the BLOSS that occurs in periodontal disease is mediated by products of the cyclooxygenase pathway. Furthermore, CO activation represents a major regulatory step in bone destruction and may thereby serve as an important site for pharmacological modulation.</description><subject>Administration, Oral</subject><subject>Administration, Topical</subject><subject>Alveolar Bone Loss - drug therapy</subject><subject>Alveolar Bone Loss - metabolism</subject><subject>Analysis of Variance</subject><subject>Animals</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - administration &amp; dosage</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</subject><subject>Biological and medical sciences</subject><subject>bone loss</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>Cyclooxygenase Inhibitors - pharmacology</subject><subject>cyclooxygenase metabolites</subject><subject>Dentistry</subject><subject>Dinoprostone - metabolism</subject><subject>Dogs</subject><subject>Flurbiprofen - administration &amp; dosage</subject><subject>Flurbiprofen - pharmacology</subject><subject>Gingival Crevicular Fluid - chemistry</subject><subject>Ibuprofen - administration &amp; dosage</subject><subject>Ibuprofen - pharmacology</subject><subject>Medical sciences</subject><subject>Naproxen - administration &amp; dosage</subject><subject>Naproxen - pharmacology</subject><subject>NSAIDs</subject><subject>Pharmacology. Drug treatments</subject><subject>Prostaglandins F - metabolism</subject><subject>Thromboxane B2 - metabolism</subject><issn>0022-3484</issn><issn>1600-0765</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkF1v0zAUhi0EGqXwE5AshLhLcOLYjrlAGlsZm6bxrSFxYfnjZErnxsVOof33uEpVrvGNbZ33POfoQehFRcoqn9fLsuKEFERwVlZS1uVoSMUFKbcP0OxYeohmhNR1QZu2eYyepLQk-c-FPEEnOdQS2szQz0XXgR0TDh2--Xp6eZ5fAzag7zxgG-F3bzdeR2x31oew3d3BoBPgFYzaBN-PkLAeHF5D7IMLw6g9NmEA7ENKT9GjTvsEzw73HH1_v_h29qG4_nhxeXZ6XVhGalEIYg1xWoOtnWtaB0Ja1nKm24bqqmKWAlhw0jXWaFIR1krWNaY1wEnTMU7n6NXEXcfwawNpVKs-WfBeDxA2SYlaSi4zbY7eTEEb83oROrWO_UrHnaqI2ptVS7XXp_b61N6sOphV29z8_DBlY1bg_rVOKnP95aGuk9W-i3qwfTrGGOVNRuXY2yn2p_ew-48F1NWXRU1EBhQToE8jbI8AHe8VF1QwdXtzoT5_uqI_3tFzdUv_AlGmpcc</recordid><startdate>199205</startdate><enddate>199205</enddate><creator>Offenbacher, S.</creator><creator>Williams, R. C.</creator><creator>Jeffcoat, M. K.</creator><creator>Howell, T. H.</creator><creator>Odle, B. M.</creator><creator>Smith, M. A.</creator><creator>Hall, C. M.</creator><creator>Johnson, H. G.</creator><creator>Goldhaber, P.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199205</creationdate><title>Effects of NSAIDs on beagle crevicular cyclooxygenase metabolites and periodontal bone loss</title><author>Offenbacher, S. ; Williams, R. C. ; Jeffcoat, M. K. ; Howell, T. H. ; Odle, B. M. ; Smith, M. A. ; Hall, C. M. ; Johnson, H. G. ; Goldhaber, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5027-70cb0daaec2dd48de79c5865a843a115c3eeced9d4cba0105895f4b8be604f563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Administration, Oral</topic><topic>Administration, Topical</topic><topic>Alveolar Bone Loss - drug therapy</topic><topic>Alveolar Bone Loss - metabolism</topic><topic>Analysis of Variance</topic><topic>Animals</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - administration &amp; dosage</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</topic><topic>Biological and medical sciences</topic><topic>bone loss</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>Cyclooxygenase Inhibitors - pharmacology</topic><topic>cyclooxygenase metabolites</topic><topic>Dentistry</topic><topic>Dinoprostone - metabolism</topic><topic>Dogs</topic><topic>Flurbiprofen - administration &amp; dosage</topic><topic>Flurbiprofen - pharmacology</topic><topic>Gingival Crevicular Fluid - chemistry</topic><topic>Ibuprofen - administration &amp; dosage</topic><topic>Ibuprofen - pharmacology</topic><topic>Medical sciences</topic><topic>Naproxen - administration &amp; dosage</topic><topic>Naproxen - pharmacology</topic><topic>NSAIDs</topic><topic>Pharmacology. Drug treatments</topic><topic>Prostaglandins F - metabolism</topic><topic>Thromboxane B2 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Offenbacher, S.</creatorcontrib><creatorcontrib>Williams, R. C.</creatorcontrib><creatorcontrib>Jeffcoat, M. K.</creatorcontrib><creatorcontrib>Howell, T. H.</creatorcontrib><creatorcontrib>Odle, B. M.</creatorcontrib><creatorcontrib>Smith, M. A.</creatorcontrib><creatorcontrib>Hall, C. M.</creatorcontrib><creatorcontrib>Johnson, H. G.</creatorcontrib><creatorcontrib>Goldhaber, P.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of periodontal research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Offenbacher, S.</au><au>Williams, R. C.</au><au>Jeffcoat, M. K.</au><au>Howell, T. H.</au><au>Odle, B. M.</au><au>Smith, M. A.</au><au>Hall, C. M.</au><au>Johnson, H. G.</au><au>Goldhaber, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of NSAIDs on beagle crevicular cyclooxygenase metabolites and periodontal bone loss</atitle><jtitle>Journal of periodontal research</jtitle><addtitle>J Periodontal Res</addtitle><date>1992-05</date><risdate>1992</risdate><volume>27</volume><issue>3</issue><spage>207</spage><epage>213</epage><pages>207-213</pages><issn>0022-3484</issn><eissn>1600-0765</eissn><abstract>This investigation focuses on the changes in the concentrations of cyclooxygenase (CO) products present within the crevicular fluid in naturally‐progressing periodontitis in the beagle and the effects of various non‐steroidal anti‐inflammatory drugs (NSAIDs) on these metabolite levels and disease progression. Six groups of 5–6 beagles with periodontitis were followed for 6 months to determine the pretreatment rate of radiographic bone loss. At baseline, groups of animals were placed on soft chow to promote disease progression. Groups were treated with either placebo, three different formulations of systemic ibuprofen, systemic naproxen or topical flurbiprofen. During the 6‐month treatment phase, crevicular fluid (CF) samples and radiographs were taken at regular intervals. Radioimmunoassay of CF samples from untreated animals demonstrated a steady increase in prostaglandin E2 (PGE 2) over baseline values. At 1 month, CF‐PGE2 levels increased 2‐fold over baseline and, by 6 months, had reached a 5‐ to 6‐fold elevation. Crevicular fluid thromboxane B2 (CF‐TxB2) levels rapidly reached a 4‐ to 5‐fold peak over baseline at 1 month and subsequently dropped to a 2‐fold elevation for the remainder of the study. The rate of bone loss (BLOSS) in untreated animals increased 38% during the 6‐month period, as compared to baseline pretreatment BLOSS rates. Overall, there was a significant depression in the CF levels of both PGE2 and TxB2 in all NSAID‐treated groups. All NSAID treatments significantly retarded BLOSS, ranging from 21.0–36.9% of the control BLOSS rate. The topical application of flurbiprofen was as effective in depressing CF levels of PGE2 and TxB2 as systemic or sustained release formulations of other NSAIDs. The data further substantiate the concept that much of the BLOSS that occurs in periodontal disease is mediated by products of the cyclooxygenase pathway. Furthermore, CO activation represents a major regulatory step in bone destruction and may thereby serve as an important site for pharmacological modulation.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>1608034</pmid><doi>10.1111/j.1600-0765.1992.tb01670.x</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-3484
ispartof Journal of periodontal research, 1992-05, Vol.27 (3), p.207-213
issn 0022-3484
1600-0765
language eng
recordid cdi_proquest_miscellaneous_72996984
source Wiley-Blackwell Journals; MEDLINE
subjects Administration, Oral
Administration, Topical
Alveolar Bone Loss - drug therapy
Alveolar Bone Loss - metabolism
Analysis of Variance
Animals
Anti-Inflammatory Agents, Non-Steroidal - administration & dosage
Anti-Inflammatory Agents, Non-Steroidal - pharmacology
Biological and medical sciences
bone loss
Bones, joints and connective tissue. Antiinflammatory agents
Cyclooxygenase Inhibitors - pharmacology
cyclooxygenase metabolites
Dentistry
Dinoprostone - metabolism
Dogs
Flurbiprofen - administration & dosage
Flurbiprofen - pharmacology
Gingival Crevicular Fluid - chemistry
Ibuprofen - administration & dosage
Ibuprofen - pharmacology
Medical sciences
Naproxen - administration & dosage
Naproxen - pharmacology
NSAIDs
Pharmacology. Drug treatments
Prostaglandins F - metabolism
Thromboxane B2 - metabolism
title Effects of NSAIDs on beagle crevicular cyclooxygenase metabolites and periodontal bone loss
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T19%3A01%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20NSAIDs%20on%20beagle%20crevicular%20cyclooxygenase%20metabolites%20and%20periodontal%20bone%20loss&rft.jtitle=Journal%20of%20periodontal%20research&rft.au=Offenbacher,%20S.&rft.date=1992-05&rft.volume=27&rft.issue=3&rft.spage=207&rft.epage=213&rft.pages=207-213&rft.issn=0022-3484&rft.eissn=1600-0765&rft_id=info:doi/10.1111/j.1600-0765.1992.tb01670.x&rft_dat=%3Cproquest_cross%3E72996984%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72996984&rft_id=info:pmid/1608034&rfr_iscdi=true